Suppr超能文献

用马来酸酐-二乙烯基醚-2治疗小鼠肿瘤的人工转移和自发转移

Therapy of artificial and spontaneous metastases of murine tumors with maleic anhydride-divinyl ether-2.

作者信息

Milas L, Hersh E M, Hunter N

出版信息

Cancer Res. 1981 Jun;41(6):2378-85.

PMID:7237436
Abstract

A 15,500 molecular-weight fraction of a pyran copolymer, (MVE-2) was investigated for its therapeutic efficacy against artificial lung metastases of a weakly immunogenic spontaneous fibrosarcoma (NFSa), a relatively strongly immunogenic fibrosarcoma (FSa), a moderately immunogenic spontaneous mammary carcinoma (MCa-K-, and a weakly immunogenic spontaneous mammary carcinoma (MDAH-MCa-4) syngeneic to C3Hf/Kam mice. In addition, the therapeutic efficacy of this polyanionic compound against spontaneous lung metastases of NFSa was also determined. Systemic i.v. or i.p. application of MVE-2 in doses ranging from 10 to 50 mg/kg body weight greatly reduced the number of artificial NFSa lung metastases and prolonged the survival of the mice. Multiple injections of MVE-2 given at weekly intervals were more effective than were single treatments. Although various treatment schedules with MVE-2 were capable of reducing the number of metastases and prolonging survival of tumor-bearing mice, no cures were observed. A therapeutic effect was also evident against spontaneous lung metastases of NFSa. The effect, however, was more profound when MVE-2 was given before rather than after surgical removal of the primary tumor. MVE-2 was not effective in mice exposed previously to whole-body or local thoracic irradiation. In contrast, MVE-2 protected mice against enhancement of lung metastases induced by exposure of the mice to these irradiations. NFSa growing i.m. promoted the formation of lung metastases from tumor cells given i.v. This concomitant enhancement of metastases was abolished by treatment of the mice with MVE-2. MVE-2 was also effective against tumor deposits in the other three tumors. The extent of its therapeutic efficacy was independent of tumor immunogenicity. These results suggest several approaches to the clinical application of MVE-2 and provide additional data on the therapeutic activity of the pyran copolymer derivatives in different animal models.

摘要

对一种吡喃共聚物(MVE - 2)的15,500分子量级分进行了研究,以考察其对C3Hf/Kam小鼠同基因的弱免疫原性自发性纤维肉瘤(NFSa)、相对强免疫原性纤维肉瘤(FSa)、中度免疫原性自发性乳腺癌(MCa - K -)以及弱免疫原性自发性乳腺癌(MDAH - MCa - 4)人工肺转移瘤的治疗效果。此外,还测定了该聚阴离子化合物对NFSa自发性肺转移瘤的治疗效果。以10至50毫克/千克体重的剂量经静脉或腹腔全身给予MVE - 2,可显著减少人工NFSa肺转移瘤的数量,并延长小鼠存活时间。每周间隔多次注射MVE - 2比单次治疗更有效。尽管MVE - 2的各种治疗方案都能减少转移瘤数量并延长荷瘤小鼠的存活时间,但未观察到治愈情况。对NFSa自发性肺转移瘤也有明显的治疗效果。然而,当在手术切除原发肿瘤之前而非之后给予MVE - 2时,效果更为显著。MVE - 2对先前接受过全身或局部胸部照射的小鼠无效。相反,MVE - 2可保护小鼠免受因接受这些照射而导致的肺转移增强。皮下生长的NFSa促进了经静脉注射的肿瘤细胞形成肺转移瘤。用MVE - 2治疗小鼠可消除这种转移的伴随增强现象。MVE - 2对其他三种肿瘤的瘤块也有效。其治疗效果的程度与肿瘤免疫原性无关。这些结果提示了MVE - 2临床应用的几种方法,并提供了关于吡喃共聚物衍生物在不同动物模型中治疗活性的更多数据。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验